Full text
Earnings transcript
Read the complete earnings call transcript.
AUTL
Autolus Therapeutics plc
$1.41
0.03
(2.17%)
| Exchange: | NASDAQ |
| Market Cap: | 375.262M |
| Shares Outstanding: | 13.783M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Christian Martin Itin | |||||
| Full Time Employees: | 647 | |||||
| Address: |
| |||||
| Website: | https://www.autolus.com |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1,698 | 10,120 | 75,564.172 |
| Gross Profit | 1,698 | -130,900 | -21,030.029 |
| EBITDA | -156,770 | -233,073 | -271,600.214 |
| Operating Income | -179,701 | -241,426 | -281,437.148 |
| Net Income | -208,383 | -220,662 | -287,528 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 375,381 | 782,725 | 589,068 |
| Total Liabilities | 263,907 | 355,400 | 410,939 |
| Total Stockholders Equity | 111,474 | 427,325 | 178,129 |
| Total Debt | 52,967 | 297,229 | 351,586.999 |
| Cash and Cash Equivalents | 239,566 | 227,380 | 104,132 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -145,587 | -206,271 | -283,568 |
| Capital Expenditure | -10,986 | -34,819 | -19,087.499 |
| Free Cash Flow | -156,573 | -241,090 | -303,318.160 |
| Net Income | -208,383 | -220,662 | -287,528 |
| Net Change in Cash | -143,195 | -11,530 | -123,170 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 619,434.584 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 818,050.110 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 712,293.865 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -818,050.110 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -619,434.584 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -712,293.865 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 47,588.176 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 68,360.264 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 57,299.559 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 6,884,306.851 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 9,091,691.234 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 7,916,331.541 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0.220 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0.260 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.180 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 6 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 5 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Position: AUTL demonstrates a solid balance sheet with significant cash and cash equivalents, as indicated by the Balance Sheet data (cashAndCashEquivalents, totalCurrentAssets). A favorable current ratio (currentRatioTTM) and quick ratio (quickRatioTTM) suggest strong liquidity to meet short-term obligations.
- Positive Revenue Trends: Income Statement data shows consistent revenue growth over recent periods (revenue across calendarYear and period), reflecting operational stability and potential market demand for AUTL’s offerings, particularly within specific product categories (Revenue Product Segments).
- Industry and Sector Performance: AUTL operates in a sector with favorable performance metrics (sector_perf1w, sector_perf1m, sector_perf3m), as per Industry and Sector data, indicating a supportive industry environment that may bolster stock performance relative to peers.
- Operational Efficiency: Key Metrics such as gross profit margin (grossProfitMarginTTM) and return on equity (roeTTM) suggest effective cost management and profitability, positioning AUTL as a competitive player in its industry (industryName).
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about AUTL valuation
Is Autolus Therapeutics plc (AUTL) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Autolus Therapeutics plc (AUTL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is AUTL a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AUTL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is AUTL’s P/E ratio?
You can see AUTL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for AUTL?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is AUTL a good long-term investment?
Whether AUTL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
AUTL
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
2.17
Trading Metrics:
| Open: | 1.34 | Previous Close: | 1.38 | |
| Day Low: | 1.31 | Day High: | 1.42 | |
| Year Low: | 1.11 | Year High: | 2.7 | |
| Price Avg 50: | 1.48 | Price Avg 200: | 1.69 | |
| Volume: | 1.032M | Average Volume: | 1.62M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeAUTL full analysis
Welcome to MARKETSNAP’s SWOT analysis for Autolus Therapeutics, a company that might not be on everyone’s radar just yet, but definitely deserves a closer look. If you’re a long-term investor hunting for opportunities in the biotech space, stick around because we’re diving deep into what makes this company tick, what’s holding it back, and where it could be headed. Let’s break it down with a full SWOT analysis, some key insights, and a long-term perspective to help you decide if…
